Molecular Biology and Inhibitors of Hepatitis A Virus
Molecular Biology and Inhibitors of Hepatitis A Virus
复制标题
DOI：
10.1002/med.21292
复制
发表时间：
2014-09-01
影响因子：
13.3
通讯作者：
Thibaut, Hendrik Jan
中科院分区：
文献类型：
--
作者：
Debing, Yannick;Neyts, Johan;Thibaut, Hendrik Jan
甲型肝炎病毒（HAV）是一种经粪便传播的小核糖核酸病毒，是全世界急性肝炎的主要原因之一。概述了 HAV 的分子生物学，重点介绍了最近的发现。还讨论了免疫逃避策略以及 HAV 和特应性之间可能的相关性。尽管有有效的疫苗，但仍需要针对 HAV 的抗病毒药物来治疗严重的暴发性肝炎病例、控制疫情并阻止疫苗逃逸变种的潜在传播。此外，此类药物可用于缩短病程并降低相关的经济成本。将讨论具有不同作用机制的几种已知的HAV抑制剂。由于这些分子都不容易在临床上使用，并且抗 HAV 药物的可用性具有临床重要性，因此应加大力度发现和开发此类抗病毒药物。 (C) 2013 年 Wiley 期刊公司。
Hepatitis A virus (HAV) is a faeco-orally transmitted picornavirus and is one of the main causes of acute hepatitis worldwide. An overview of the molecular biology of HAV is presented with an emphasis on recent findings. Immune evasion strategies and a possible correlation between HAV and atopy are discussed as well. Despite the availability of efficient vaccines, antiviral drugs targeting HAV are required to treat severe cases of fulminant hepatitis, contain outbreaks, and halt the potential spread of vaccine-escape variants. Additionally, such drugs could be used to shorten the period of illness and decrease associated economical costs. Several known inhibitors ofHAVwith various mechanisms of action will be discussed. Since none of these molecules is readily useable in the clinic and since the availability of an anti-HAV drug would be of clinical importance, increased efforts should be targeted toward discovery and development of such antivirals. (C) 2013 Wiley Periodicals, Inc.